In this issue of Clinical Cancer Research, Flavin and colleagues evaluated SPINK1 expression by immunohistochemistry (IHC) in prostate cancer resection specimens from participants in the U.S. Physician's Health Study and Health Professionals Follow-Up Study (1) . Flavin and colleagues found that 8% of cases were SPINK1-positive (SPINK1 þ ), with no association with biochemical recurrence or prostate cancer-related mortality. Importantly, this study was performed in a large, well-annotated clinical cohort with prostate cancer-specific mortality as a definitive endpoint. As described below, we have previously proposed prostate cancer molecular subtyping based on mutually exclusive SPINK1 and ERG overexpression (2, 3) . Although Flavin and colleagues again report significant exclusivity, SPINK1 expression was observed in 47 of 427 (11%) ERG-negative (ERG À ) cases and 19 of 427 (4%) ERG-positive (ERG þ ) cases, the latter challenging the more absolute degree of exclusivity reported previously. Overall, this study provides helpful independent confirmation of the prevalence of these molecular groups in an exceptionally well-annotated North American cohort with follow-up; it also makes suggestive observations about cellular signaling pathways thought to be downstream of SPINK1 that may be of translational and therapeutic relevance. However, the observations about apparent incomplete mutual exclusivity between SPINK1 þ and ERG þ prostate cancer raise interesting and important issues about prostate cancer subtyping, IHC, and testing prognostic biomarkers. In 2008, through expression profiling meta-analysis, we reported that approximately 10% of prostate cancer showed marked SPINK1 overexpression (3) and that almost all SPINK1-overexpressing cases lacked ERG rearrangements. Previously, we had shown that ERG overexpression, occurring in approximately 50% of PSA-screened prostate cancer from Caucasian populations, was driven by chromosomal rearrangements bringing the ERG locus under the supraphysiologic transcriptional regulation of a number of genes, most androgen regulated, and most frequently TMPRSS2 (2). By combined IHC/FISH, we found that 9% of prostate cancer cases were SPINK1 þ , and that these cases were exclusively ERG rearrangement negative (ERG À ; Fig. 1A Lending to the lack of clarity in the literature for biomarkers, including SPINK1 in prostate cancer, are a number of issues, which may be intrinsic to the experiment (differing techniques, analytes studied, antibodies/protocols used, and criteria and thresholds for "positivity"), the cohort (demography, differences in treatment, follow-up protocols), or even the disease studied (for prostate cancer, the remarkable degree of multifocality as described below). About technical issues, previous studies in contemporary PSA-screened Caucasian cohorts have consistently shown that approximately 10% of prostate cancers show marked SPINK1 transcript overexpression (3, 5) . In keeping with these reports, in Fig. 1B expression from 11 prostate cancer datasets in the Oncomine database, including five studies not included in our original analysis. In contrast, much greater variability in SPINK1 positivity (5%-99%) has been observed in IHC studies, with the 8% reported by Flavin and colleagues consistent with other studies using the 4D4 antibody clone (Fig. 1A) .
Similarly, conflicting results about SPINK1 and prostate cancer prognosis have been reported (Fig. 1A) , which likely pertain to both technical and cohort-dependent differences. Although we first observed SPINK1 outlier expression to be associated with biochemical recurrence after prostatectomy in an mRNA expression profiling study and in two IHC-based studies of referral prostatectomy series (3), the negative results with respect to prognosis reported by Flavin and colleagues among participants in the U.S. Physicians' Health Study and Health Professionals Follow-Up Study are more consistent with negative results in recent large prostatectomy series (6, 7) . Caveats related to biases and even interventions (e.g., vitamins) undertaken in the Physicians cohorts merit consideration. Nonetheless, the cases represented in the Flavin and colleagues cohort add to recent experience finding little to no support for use of SPINK1 as a prognostic biomarker following prostatectomy.
Finally, most intriguing are the disease-specific issues about prostate cancer biomarker testing, as were noted in this study. The overall 2% ERG þ /SPINK1 þ rate reported by Flavin and colleagues is the highest rate of dual positivity reported, at least using the 4D4 SPINK1 antibody clone (Fig. 1A) . Prostate cancer is commonly multifocal, with most men at resection harboring multiple, clonally independent tumor foci, further complicating subtyping and prognostic studies, particularly those reliant on tissue microarrays (TMA; Fig. 1C-F (4, 8, 11, 12) . Critically, collision tumors complicate the interpretation of replicate index focus TMA cores that show discordant ERG status. In our opinion, they indicate the presence of multiple genetically distinct foci, and such cores should be considered independently or resolved through whole-section evaluation. Hence, the 7 of 19 ERG þ /SPINK1 þ cases described by Flavin and colleagues with discordant ERG þ /SPINK1 þ status in TMA cores are challenging to interpret without whole-section evaluation. Interestingly, in the 3 ERG þ /SPINK1 þ cases evaluated on whole sections by Flavin and colleagues and in the one observed in our recent series (12) , only small areas of dual positivity were observed in otherwise ERG þ /SPINK1 À foci. Such observations underscore the value of whole-section-based studies, and, given the lack of homogeneous ERG þ /SPINK1 þ tumor foci, these exceptions seem to prove the rule observed at the transcript level. Finally, and importantly with respect to criteria for positivity, in whole-section-based studies, we commonly (7) were presumably included in the study by Grupp et al. (6) . B, normalized gene expression (Z-score units) for ERG and SPINK1 in 587 localized prostate cancers is plotted from 11 microarray studies in the Oncomine database. The lack of ERG/SPINK1 coexpression supports marked overexpression of ERG (ERG þ , blue) or SPINK1 (SPINK1 þ , yellow) as defining unique prostate cancer molecular subtypes (approximate frequencies in PSA-screened Caucasian cohorts shown in the inset). C-F, prostate cancer multifocality confounds molecular subtyping and biomarker evaluation. At prostatectomy, most men with prostate cancer harbor multiple genetically distinct cancer clones. C, the largest/highest-grade focus (index focus, gray) is used to assign pathology and smaller/lower-grade foci (white) are not specifically described. To facilitate IHC or molecular assays across large cohorts, replicate cores (black circles) are often taken from the index focus to generate. D-F, multiple groups have evaluated ERG and/or SPINK1 by IHC using whole sections or TMAs. D, in our experience, ERG is nearly always homogeneously present or absent in a given focus and replicate TMA cores ( observe heterogeneous SPINK1 expression, both in intensity and percentage, with particularly strong staining in the leading edge of tumors (8, 12) . Given the lack of prognostic ability of SPINK1 in prostatectomy series, the major near-term utility of this biomarker will likely be in subtyping. Hence, careful whole-section evaluation of genetic, transcript, and protein expression will likely be required to conclusively evaluate subtyping based on ERG/SPINK1/SPOP status and other biomarkers. Similar studies will also be required to advance prognostic biomarkers into routine practice.
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